- Home
- OPT vs KREF Comparison
OPT vs KREF Comparison
Compare OPT & KREF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- KREF
- Stock Information
- Founded
- OPT 1984
- KREF 2014
- Country
- OPT Australia
- KREF United States
- Employees
- OPT N/A
- KREF N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- KREF Real Estate Investment Trusts
- Sector
- OPT Health Care
- KREF Real Estate
- Exchange
- OPT Nasdaq
- KREF Nasdaq
- Market Cap
- OPT 767.9M
- KREF 784.1M
- IPO Year
- OPT 2020
- KREF 2017
- Fundamental
- Price
- OPT $3.22
- KREF $10.40
- Analyst Decision
- OPT Strong Buy
- KREF Buy
- Analyst Count
- OPT 1
- KREF 6
- Target Price
- OPT $12.00
- KREF $12.75
- AVG Volume (30 Days)
- OPT 13.0K
- KREF 356.9K
- Earning Date
- OPT 08-30-2024
- KREF 02-04-2025
- Dividend Yield
- OPT N/A
- KREF 9.29%
- EPS Growth
- OPT N/A
- KREF N/A
- EPS
- OPT N/A
- KREF N/A
- Revenue
- OPT $261,859.00
- KREF $66,587,000.00
- Revenue This Year
- OPT N/A
- KREF N/A
- Revenue Next Year
- OPT $46,864.64
- KREF N/A
- P/E Ratio
- OPT N/A
- KREF N/A
- Revenue Growth
- OPT N/A
- KREF 9.58
- 52 Week Low
- OPT $1.79
- KREF $8.71
- 52 Week High
- OPT $5.45
- KREF $14.12
- Technical
- Relative Strength Index (RSI)
- OPT 40.67
- KREF 24.24
- Support Level
- OPT $3.15
- KREF $11.17
- Resistance Level
- OPT $3.78
- KREF $11.70
- Average True Range (ATR)
- OPT 0.18
- KREF 0.29
- MACD
- OPT -0.00
- KREF -0.08
- Stochastic Oscillator
- OPT 25.91
- KREF 2.19
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
About KREF KKR Real Estate Finance Trust Inc.
KKR Real Estate Finance Trust Inc is a real estate finance company that focuses on originating and acquiring senior mortgage loans secured by CRE assets. The investment is to originate or acquire senior mortgage loans collateralized by institutional-quality CRE assets that are owned and operated by experienced and well-capitalized sponsors and located in liquid markets with underlying fundamentals. KKR manages investments across multiple asset classes, including private equity, real estates, energy, infrastructure, credit, and hedge funds. The company's investment objective is capital preservation and generating attractive risk-adjusted returns for its stockholders over the long term, through dividends.